Beam Therapeutics Inc. (BEAM) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Beam Therapeutics reported revenue of $139.7M, up 120.0% from $63.5M the year before. Net income was -$80.0M (a -57.2% net margin), or -$0.81 per diluted share. Operating margin was -274.6%. Operating activities generated -$345.1M of cash, leaving -$360.0M of free cash flow. At fiscal year end, Beam Therapeutics held $1.48B in total assets against $242.8M in total liabilities, including $294.9M of cash and equivalents.
Open the full interactive Beam Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Beam Therapeutics Key Stats
| Share Price | $24.43 |
|---|---|
| Market Cap | $2.55B |
| Revenue YoY Growth | +120.0% |
| 52-Week Range | $20.60 – $37.92 |
| Shares Outstanding | 104.3 million (basic, 2026 Q2) |
Beam Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $24,000 | $51.8M | $60.9M | $377.7M | $63.5M | $139.7M |
| Operating Income | -$132.8M | -$392.5M | -$338.5M | -$176.5M | -$415.6M | -$383.7M |
| Pre-Tax Income | -$194.6M | -$370.6M | -$260.2M | -$131.2M | -$376.7M | -$80.0M |
| Income Tax | $0 | $0 | $3.4M | $1.4M | $39,000 | $0 |
| Net Income | -$194.6M | -$370.6M | -$289.1M | -$132.5M | -$376.7M | -$80.0M |
| Diluted EPS | -$4.19 | -$5.77 | -$4.13 | -$1.72 | -$4.58 | -$0.81 |
Beam Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $9.7M | $114.1M | $31.7M | $490,000 |
| Net Income | -$112.7M | $244.3M | -$94.3M | -$122.7M |
| Diluted EPS | -$1.10 | $2.47 | -$0.91 | -$1.18 |
Beam Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $162.2M | $560.0M | $232.8M | $435.9M | $282.0M | $294.9M |
| Current Assets | $308.3M | $1.27B | $1.09B | $1.21B | $878.1M | $1.27B |
| Total Assets | $451.7M | $1.47B | $1.34B | $1.46B | $1.10B | $1.48B |
| Current Liabilities | $102.3M | $213.4M | $223.6M | $205.6M | $182.1M | $96.9M |
| Total Liabilities | $206.1M | $647.7M | $608.2M | $478.4M | $370.3M | $242.8M |
| Shareholders' Equity | $245.6M | $826.7M | $733.5M | $981.3M | $733.5M | $1.24B |
Beam Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$95.7M | -$66.3M | $22.5M | -$149.2M | -$347.2M | -$345.1M |
| Cash From Investing | -$100.1M | -$294.1M | -$461.3M | $71.8M | $185.0M | -$121.4M |
| Cash From Financing | $322.3M | $756.1M | $111.6M | $276.4M | $7.7M | $478.0M |
| Free Cash Flow | -$112.1M | -$113.1M | -$26.4M | -$182.9M | -$356.2M | -$360.0M |
Figures from Beam Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Beam Therapeutics financials page for every line item.
Beam Therapeutics Company Profile
| Ticker | BEAM |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001745999 |
Frequently Asked Questions
What was Beam Therapeutics' revenue in fiscal 2025?
Beam Therapeutics (BEAM) reported revenue of $139.7M for fiscal 2025.
What is Beam Therapeutics' annual revenue history?
Beam Therapeutics' annual revenue by fiscal year: 2020: $24,000; 2021: $51.8M; 2022: $60.9M; 2023: $377.7M; 2024: $63.5M; 2025: $139.7M.
What was Beam Therapeutics' net income in fiscal 2025?
Beam Therapeutics reported net income of -$80.0M for fiscal 2025.
What was Beam Therapeutics' earnings per share (EPS) in fiscal 2025?
Beam Therapeutics' diluted EPS was -$0.81 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Beam Therapeutics generate in fiscal 2025?
Beam Therapeutics generated -$360.0M of free cash flow in fiscal 2025.
What was Beam Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Beam Therapeutics reported revenue of $490,000.
How many shares of Beam Therapeutics are outstanding?
Beam Therapeutics reported a weighted average of 104.3 million basic shares outstanding in 2026 Q2.
What is Beam Therapeutics' market cap?
Based on its latest closing price, Beam Therapeutics (BEAM) has a market capitalization of about $2.55B.
When does Beam Therapeutics' fiscal year end?
Beam Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Beam Therapeutics headquartered?
Beam Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.
Beam Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →